Archives
-
Lipidated Nanophotosensitizers Target Tumor EVs to Inhibit M
2026-06-18
The reference study introduces a lipidated nanophotosensitizer that enables tracking and disabling of tumor extracellular vesicles (TEVs), resulting in concurrent inhibition of tumor growth and metastasis in preclinical models. This dual-function platform offers a mechanistically distinct approach to antimetastatic therapy by disrupting TEV-mediated intercellular communication.
-
Phalloidin (B7678): Technical Guide for F-Actin Stabilizatio
2026-06-18
Phalloidin (SKU B7678) is a cyclic heptapeptide toxin utilized for high-affinity stabilization and visualization of filamentous actin (F-actin) in fixed or permeabilized cell samples. It is not suitable for live-cell imaging or experiments requiring reversible actin interactions, but offers robust preservation of cytoskeletal structure for microscopy-based cell biology research.
-
Bivalent mRNA Vaccine RQ3025 Confers Broad SARS-CoV-2 Protec
2026-06-17
The referenced study introduces RQ3025, a bivalent mRNA vaccine designed to target multiple SARS-CoV-2 variants by incorporating key spike protein mutations. In preclinical animal models, RQ3025 induced robust neutralizing antibodies and Th1-skewed cellular responses, demonstrating enhanced cross-variant protection and safety compared to monovalent mRNA vaccines.
-
WY-14643 (Pirinixic Acid): Precision in Lipid Metabolism Res
2026-06-17
WY-14643 (Pirinixic Acid) stands out as a benchmark selective PPARα agonist, enabling researchers to dissect metabolic and inflammatory pathways with rigor. Its robust performance in modulating lipid homeostasis and insulin sensitivity, combined with well-validated workflows, make it indispensable for metabolic disorder research and translational applications.
-
Dissecting Drug Responses in Cancer: Insights from In Vitro
2026-06-16
Schwartz's dissertation introduces a rigorous approach to in vitro drug response evaluation in cancer, distinguishing between growth inhibition and cell death via fractional and relative viability metrics. This work refines experimental interpretation and empowers researchers to better understand and benchmark anti-cancer agents, including PLK1 inhibitors.
-
Affinity-Purified Goat Anti-Mouse IgG (H+L), HRP Conjugated:
2026-06-16
Unlock next-level immunodetection with the Affinity-Purified Goat Anti-Mouse IgG (H+L), HRP Conjugated secondary antibody. This reagent, trusted by APExBIO, enables robust signal amplification and reproducibility in Western blot, ELISA, and IHC workflows—empowering translational neuroscience and disease modeling research.
-
Tunicamycin: Applied N-Glycosylation Inhibitor for ER Stress
2026-06-15
Tunicamycin empowers researchers to precisely induce ER stress and dissect N-glycosylation pathways, providing a gold-standard approach for inflammation and glycoprotein studies. With robust in vitro and in vivo protocols, APExBIO’s high-purity reagent enables reproducible results and straightforward troubleshooting.
-
Hematoxylin and Eosin Staining Kit: Technical Workflow Guide
2026-06-15
The Hematoxylin and Eosin Staining Kit (SKU: K1142) provides ready-to-use solutions for reliable visualization of cellular and tissue morphology in research histopathology. It streamlines staining workflows for both paraffin-embedded and frozen tissue sections but is not suitable for diagnostic or clinical applications.
-
Catalpol (N1352): Technical Guidance for Disease Model Resea
2026-06-14
Catalpol is a multi-target iridoid glycoside suitable for neuroprotection, osteoporosis, ischemic stroke, and liver fibrosis research in cell and animal models. This article outlines practical handling, protocol parameters, and troubleshooting steps for maximizing experimental reproducibility. It is not appropriate for clinical or cross-domain use beyond the validated preclinical frameworks described.
-
SGC-CBP30: Precision CREBBP/EP300 Inhibition in Chromatin Bi
2026-06-13
Explore how SGC-CBP30, a selective CREBBP/EP300 bromodomain inhibitor, enables precise dissection of chromatin coactivator function and super-enhancer dynamics in epigenetics research. Discover advanced assay insights and unique translational implications for cancer biology.
-
Sulfo-NHS-Biotin: Reliable Cell Surface Labeling for Functio
2026-06-12
This article provides a scenario-driven, evidence-based guide to using Sulfo-NHS-Biotin (SKU A8001) for precise cell surface protein labeling in viability, proliferation, and cytotoxicity assays. By addressing real laboratory challenges and referencing current literature, it demonstrates how this reagent enhances experimental reproducibility and workflow safety for biomedical researchers.
-
Human SAN-Plexus Assembloids Model Pacemaker Maturation
2026-06-12
This study introduces a human-specific in vitro platform integrating pluripotent stem cell-derived sinoatrial node and cardiac plexus organoids to recapitulate the neuro-cardiac interactions underlying pacemaker maturation. The assembloid model enables functional dissection of neuron-to-pacemaker signaling, offering new insights into human cardiac conduction and autonomic regulation.
-
WY-14643 (Pirinixic Acid) for Precision Metabolic Research
2026-06-11
WY-14643 (Pirinixic Acid) stands out as a gold-standard PPARα agonist, enabling researchers to dissect lipid metabolism and inflammation with reproducibility and depth. Its dual modulation of PPARα/γ and robust anti-inflammatory profile empower translational studies across metabolic disorder models.
-
Iron Stress Remodels Enterocyte Metabolism and Inflammatory
2026-06-11
Navazesh and Ji (2025) provide comprehensive mechanistic insights into how both iron deficiency and iron excess distinctly reprogram enterocyte metabolism and inflammatory gene expression in IPEC-J2 cells. Their integrated metabolomics and transcriptional analyses clarify cellular adaptation under iron stress, informing future research on intestinal physiology and iron-modulating strategies.
-
Exo1 in Translational Research: Precision Tools for TEV Inhi
2026-06-10
This thought-leadership article explores how Exo1 (methyl 2-(4-fluorobenzamido)benzoate), a next-generation membrane trafficking inhibitor, empowers translational researchers to dissect tumor extracellular vesicle (TEV) biology. By bridging mechanistic insight with strategic workflow guidance, we position Exo1 as an indispensable asset for antimetastatic research, referencing recent breakthroughs in TEV-targeted therapies and providing robust, evidence-backed protocols.